AnorMED licenses imaging technology to Bristol-Myers Squibb:
This article was originally published in Clinica
Executive Summary
Bristol-Myers Squibb Medical Imaging has licensed technology for linking the imaging isotope technetium to a tissue-targeting agent from Vancouver, Canada-based AnorMED. BMS will use the HYNIC linker technology to develop diagnostic imaging products for cardiovascular diseases. AnorMED will receive an up-front payment of $0.1m and annual payments until 2007, as well as milestons and royalties. The same HYNIC technology has also been licensed to North American Scientific, which is developing a prognostic imaging agent for cancer and other diseases.